T
Tony Vangeneugden
Researcher at Janssen Pharmaceutica
Publications - 34
Citations - 1803
Tony Vangeneugden is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Ritonavir & Darunavir. The author has an hindex of 21, co-authored 34 publications receiving 1665 citations. Previous affiliations of Tony Vangeneugden include University of Hasselt & Johnson & Johnson.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Roberto Ortiz,Edwin DeJesus,Homayoon Khanlou,Evgeniy Voronin,Jan van Lunzen,Jaime Andrade-Villanueva,Jan Fourie,Sandra De Meyer,Martine De Pauw,Eric Lefebvre,Tony Vangeneugden,Sabrina Spinosa-Guzman +11 more
TL;DR: DRV/r 800/100 mg qd was non-inferior to LPV/ r 800/200 mg at 48 weeks, with a more favorable safety profile, and offers a new effective and well tolerated once-daily, first-line treatment option for treatment-naive patients.
Journal ArticleDOI
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women
Annalene Nel,Neliëtte van Niekerk,Saidi Kapiga,Linda-Gail Bekker,Cynthia Gama,Katherine Gill,Anatoli Kamali,Philip Kotze,Cheryl Louw,Zonke Mabude,Nokuthula Miti,Sylvia Kusemererwa,Hugo Tempelman,Hannelie Carstens,Brid Devlin,Michelle Isaacs,Mariëtte Malherbe,Winel Mans,Jeremy Nuttall,Marisa Russell,Smangaliso Ntshele,Marlie Smit,Leonard Solai,Patrick Spence,John Steytler,Kathleen Windle,Maarten Borremans,Sophie Resseler,Jens Van Roey,Wim Louis Julien Parys,Tony Vangeneugden,Ben van Baelen,Zeda F. Rosenberg,Ring Study Team +33 more
TL;DR: Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.
Journal ArticleDOI
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
Christine Katlama,Roberto Esposito,José M. Gatell,Jean-Christophe Goffard,Beatriz Grinsztejn,Anton Pozniak,Jürgen K. Rockstroh,Albrecht Stoehr,N. Vetter,Patrick Yeni,Wim Louis Julien Parys,Tony Vangeneugden +11 more
TL;DR: TMC114/r demonstrated statistically higher 24-week virological response rates and CD4 cell count increases than CPI(s) and has received regulatory approval in treatment-experienced patients.
Journal ArticleDOI
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
Jean-Michel Molina,Calvin J. Cohen,Christine Katlama,Beatriz Grinsztejn,Artur Timerman,Rogério De Jesus Pedro,Tony Vangeneugden,Diego Miralles,Sandra De Meyer,Wim Louis Julien Parys,Eric Lefebvre +10 more
TL;DR: In this larger set of treatment-experienced patients, darunavir/r at a dose of 600/100 mg twice daily provided substantial virologic and immunologic responses and was generally safe and well tolerated.
Journal ArticleDOI
Applying Concepts of Generalizability Theory on Clinical Trial Data to Investigate Sources of Variation and Their Impact on Reliability
TL;DR: This work shows how full modeling power in mixed models can be used to study generalizability using data from five double-blind randomized clinical trials, comparing the effects of risperidone to conventional antipsychotic agents for the treatment of chronic schizophrenia.